Search results for #SparingVision
SparingVision will be at various upcoming conferences showcasing our gene-agnostic programs. Be sure to catch the SparingVision team at the following sessions detailed in the video below and our website! sparingvision.com/sparingvision-… #SparingVision #Conferences #Presentation
Mark your calendars! ✍️ Our team will be attending various conferences and events in the second half of 2025. sparingvision.com/sparingvision-… #SparingVision #SPVN #Ophthalmology #GeneTherapy #GenomicMedicines
Next week, the SparingVision team will be in Bruges, Belgium for Bio€quity Europe 2025 from 12-14 May. If you would like to schedule a meeting, send us a message ✍️ conferences.biocentury.com/bioequity-euro… #BEE25 #SparingVision #Investor #Biotech #BioEquity
🎉 2024 has been an incredible year for #SparingVision: 🚀 Significant progress in our PRODYGY Phase I/II clinical trial for SPVN06 🏥 Presented promising safety data and our novel triplex digital PCR assay to detect rcAAVs at major conferences 🌟Thank you, SPVN team!
🎉 What an incredible week at #ESGCT2024 in Rome! 🌍✨We had an insightful and productive time connecting with fellow experts, sharing breakthroughs, and exploring the latest advancements in gene therapy. #GeneTherapy #Innovation #SparingVision #ESGCT
🚀SparingVision is heading to #BioJapan2024! We're keen to engage in impactful discussions on the latest in biotech and gene therapy. 🧬 Meet us in PACIFICO Yokohama from 9-11 October. 🗓️ #GeneTherapy #Biotech #SparingVision #Ophthalmology #BioJapan
Yesterday, our CEO Stephane Boissel spoke with @biotechtvhq in our offices in Paris about SparingVision, our progress and mission to pioneer genomics to save sight and create a future free from blinding retinal diseases. #SparingVision #GenomicMedicine #Ophthalmology #BiotechTV
Yesterday, our CEO Stephane Boissel spoke with @biotechtvhq in our offices in Paris about SparingVision, our progress and mission to pioneer genomics to save sight and create a future free from blinding retinal diseases. #SparingVision #GenomicMedicine #Ophthalmology #BiotechTV
We will be at the Retinal Imaging Biomarkers & Endpoints Summit in Boston, June 25-27. 📅 📍 Looking forward to discussing the latest in retinal imaging for clinical trials. 👁️ #RetinalImagingSummit #Ophthalmology #SparingVision
Mark your calendars ✍️ our team will be attending various conferences and events in the second half of 2024. sparingvision.com/sparingvision-… #SparingVision #SPVN #Ophthalmology #AdvancedTherapy
🌟 #BioEquityEurope2024 was a hit! Thrilled to see @BoisselStephane, our CEO, share our breakthroughs in retinal disease treatments. Inspiring talks and great networking! #SparingVision #Innovation
Today, our CMO Daniel C. Chung, DO, MA will be presenting at the BioLabs Investor Day in Philadelphia at The Curtis. We hope to see you there! biolabsinvestorday.com/philadelphia-24 #BioLabs #SparingVision #CellandGene #Genetherapy #Ophthalmology #InvestorDay
Our Supplies and Sample Manager, Lucile Bauché will be on the ground in Munich next week attending the Precision in Pharma Supply Chain & Logistics Summit from 15-16 April. events.precision-globe.com/single-event/p… #SparingVision #Genetherapy #Ophthalmology
Next week our team will be in Rome 🇮🇹 for @alliancerm's annual Cell and Gene #MeetingOnTheMed from 9-11 April. Meet with our CMO, Daniel Chung, CR&QO, Marie Uguen and VP CorpDev, Rafaella Toso to learn more about SparingVision. meetingonthemed.com #SparingVision
🌟 2023 has been a fantastic year for #SparingVision: 🚀 Launching PRODYGY, our Phase I/II gene therapy trial of SPVN06 🤝 Welcoming Joe Papa as Chairman 🏆 Named a #Fierce15 company 🏅 Positive safety data from our PRODYGY trial 🎯 Second target selected with @intelliatx
Excited to be in Paris for a @SparingVision board meeting this week! A privilege to spend time with such an amazing team with brilliant minds using cutting-edge science to create a brighter future for ocular health. #SparingVision #Biotech #GeneTherapy
2022 has been a fantastic year of growth for #SparingVision – announcing #IND clearance, raising €75 million in #SeriesB, and presenting our science at many conferences all around the world. Discover more about us here: sparingvision.com
#startup #SparingVision, membre du classement FT120 souhaite financer les premiers essais sur l'Homme de deux candidats médicaments visant à réduire voire arrêter la progression de la rétinite pigmentaire, une maladie génétique 😲👍 usine-digitale.fr/article/la-sta…
It’s #RareDiesaseDay2022, an event aimed at providing access to diagnosis and therapies to people affected by rare diseases. At #SparingVision we are developing a unique gene independent approach to treat inherited retinal diseases. Find out more here: sparingvision.com
The February issue of @MedNous is out featuring an article on genome editing for ocular diseases by #sparingvision and an interview with #alnylam on RNAi therapies. We also report on the global distribution of Covid-19 vaccines. Contact [email protected].
Happy New Year from the team at #SparingVision! We wish everyone a prosperous, happy and healthy 2022. #HappyNewYear #Ophthalmology
